Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps — glp1.how · GLP-1 Guides
Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
Losing a lot of weight usually costs a small amount of bone, mostly at the hip, and GLP-1 weight loss is no exception. So far the fracture data are reassuring and the drug itself does not look like the main cause, but the long-term evidence is thin. Here's what the bone-density and fracture studies show, who should pay the most attention, and the levers that kept bone steady in trials: resistance and impact training, protein, calcium and vitamin D, and a well-timed bone scan.
Updated Sep 26, 2026Evidence-backed
In a Danish trial published in 2024, adults who had just lost weight on a low-calorie diet spent a year on liraglutide, on an exercise program, on both, or on placebo. The people on liraglutide alone lost more hip and spine bone density than the people who only exercised, even though the two groups lost similar amounts of weight. The people who combined the medication with exercise lost the most weight of anyone, and their bone density held steady (Jensen et al., JAMA Network Open, 2024, DOI ↗ (external link)).
The wider evidence mostly points the same way. Losing a lot of weight usually costs some bone, the GLP-1 itself does not look like the main culprit, and what you do alongside the medication decides how much bone you keep.
Why weight loss costs bone
Bone is living tissue that adjusts to the load it carries. Carrying extra body weight loads the skeleton every time you stand, walk, or climb stairs, and bone responds by staying denser. Take the load away and the body slowly removes bone it no longer "needs." Hormones play a part too: fat tissue makes estrogen, and appetite hormones and calorie intake both affect bone turnover.
This happens with any kind of weight loss, not only with medication. A meta-analysis of 41 diet-only weight-loss studies found a small but real drop in total-hip bone mineral density (BMD) after 6 to 24 months, about 0.010 to 0.015 g/cm², with no significant change at the lumbar spine (Zibellini et al., Journal of Bone and Mineral Research, 2015, DOI ↗ (external link)). The authors called the loss small next to the metabolic benefits of losing excess weight. The hip is the site to watch, and it is also where a fracture does the most damage later in life.
Losing a lot of weight on any program usually costs a small amount of bone, mostly at the hip, and GLP-1 weight loss is no exception. The drug itself does not look like the main cause: studies link the bone loss to how much weight is lost, and large reviews describe the medications' direct effect on bone as neutral or slightly negative rather than clinically significant. The clearest trial, with liraglutide, found that combining the medication with exercise kept bone density steady.
Do GLP-1s increase fracture risk?
So far the evidence says no. Two 2026 meta-analyses, one covering about 1.25 million people and one covering 43 randomized trials, found no increase in fractures with GLP-1 medications. The caveats are that most trials were not designed to measure fractures, follow-up is short, and many participants had diabetes, so 'no fracture signal so far' is the honest summary rather than proof of no risk.
Who should worry most about bone health on a GLP-1?
Postmenopausal women, adults over about 65 (men included), anyone who already has osteopenia, osteoporosis, or a fracture from a minor fall, and people losing weight very fast with little protein or exercise. Long-term steroid use, smoking, heavy drinking, and past bariatric surgery also raise the stakes.
What is the best way to protect my bones while losing weight on a GLP-1?
Resistance training is the biggest lever: in trials it made the difference between losing hip bone and keeping it, and heavy lifting plus impact work raised bone density in postmenopausal women with low bone mass. Add enough protein despite a smaller appetite, cover calcium (about 1,000 to 1,200 mg a day depending on age and sex) and vitamin D, and avoid extremely fast weight loss on very little food.
Evidence: For & Against
Both sides of the topic, so you can weigh the evidence yourself.
7Supporting
Revision history
Last updated · 6 revisions recorded.
Show what changed
v6
Evidence sources 10 → 13
v5
Body revised
v4
Published
v3
Common questions 0 → 5
v2
Evidence sources 0 → 10
v1
Created
Improve this page▾
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
GLP-1 medications produce more weight loss than most diets, often 15 to 20% of body weight on semaglutide or tirzepatide in the main obesity trials (STEP 1, DOI ↗ (external link); SURMOUNT-1, DOI ↗ (external link)). More weight lost generally means more load removed, so the question is reasonable even if the drug itself is neutral for bone.
What GLP-1 studies show about bone density
The evidence is mixed, and it helps to separate three kinds of study.
Randomized trials with bone scans. The Jensen trial above is the clearest one in people without diabetes. Over 52 weeks, liraglutide alone reduced hip and spine BMD more than exercise alone despite similar weight loss, while liraglutide plus exercise kept BMD level with placebo. That trial used liraglutide, an older and weaker GLP-1. As of September 2026 we did not find a published randomized trial reporting hip or spine BMD for semaglutide or tirzepatide in people with obesity alone, which is a real gap in the evidence.
Real-world scans in higher-risk patients. A 2026 single-center study followed 255 people on semaglutide or tirzepatide (92% women, average age 64) who already had DXA scans for bone health, and compared them with matched non-users. After a median of 17 months and about 5% weight loss, both groups lost hip bone at a similar rate overall. Among people without diabetes, though, GLP-1 users lost more total-hip bone (about 1% versus 0.6% a year), and more weight lost went with more bone lost (Liu et al., Journal of Clinical Endocrinology & Metabolism, 2026, DOI ↗ (external link)). The authors concluded that weight loss, not the drug itself, seemed to drive the bone loss.
Studies in people with diabetes. Here the results lean neutral to positive. A network meta-analysis of 33 trials in type 2 diabetes reported BMD gains and a lower fracture risk with long-term GLP-1 treatment, though the authors cautioned that trials shorter than a year are hard to interpret (Alalwani et al., BMC Musculoskeletal Disorders, 2025, DOI ↗ (external link)). Diabetes changes bone in its own ways, so these results may not carry over to people taking a GLP-1 only for weight.
A 2025 expert review summed it up: in clinical studies GLP-1 medications have a neutral or slightly negative effect on bone turnover and BMD, not a clinically significant one, and fracture risk does not seem to rise at normal doses (Anastasilakis et al., Diabetes, Obesity & Metabolism, 2025, DOI ↗ (external link)).
What about fractures?
BMD is a stand-in. What matters is whether bones actually break, and so far the fracture data are reassuring.
A 2026 meta-analysis of 60 studies (46 randomized trials plus real-world data, about 1.25 million people) found no effect of GLP-1 medications on BMD or fractures at any site once the best-adjusted estimates were used. It did find a consistent drop in lean mass (Beaudart et al., Drugs, 2026, DOI ↗ (external link)).
A 2026 meta-analysis of 43 randomized trials with about 100,000 participants found no difference in reported osteoporotic fractures between GLP-1 users and controls (Cao et al., Therapeutic Advances in Musculoskeletal Disease, 2026, DOI ↗ (external link)).
There are limits here. Most of these trials were not designed to measure fractures, fractures are rare over one or two years, and many participants had diabetes. Fractures from bone lost now could show up a decade later, beyond what any trial has followed. "No fracture signal so far" is the honest summary. It is not proof that there is no risk.
Who should pay the most attention
Everyone loses a little bone when they lose a lot of weight. For some people that small loss matters more:
Postmenopausal women. Bone loss speeds up after menopause as estrogen falls, so a weight-loss dip adds to a decline that is already under way. Our guide on HRT for women and GLP-1 medications covers how hormone therapy fits in, and the women's health on a GLP-1 guide covers the wider picture.
Adults over about 65, men included. Older bones start with less reserve, and falls are more likely.
Anyone who already has osteopenia or osteoporosis, or a past fracture from a minor fall.
People losing weight very fast or very far, especially with a low protein intake and little exercise.
People with other bone risks, such as long-term steroid use, low body weight at the end of treatment, heavy drinking, smoking, or conditions that affect calcium absorption, including past bariatric surgery.
How to protect your bones
The good news from the trials is that bone loss is largely preventable. These are the levers with the best evidence.
1. Lift, and add some impact
This is the biggest lever. In the Jensen trial, exercise was the difference between losing bone and keeping it. In older adults dieting to lose about 9% of their weight, programs that included resistance training limited hip bone loss to about 0.5 to 1%, compared with about 3% for aerobic exercise alone (Villareal et al., New England Journal of Medicine, 2017, DOI ↗ (external link)). Bone responds to heavy, fast loading. In the LIFTMOR trial, postmenopausal women with low bone mass who did supervised heavy lifting and jumping twice a week for 8 months gained spine and hip BMD, while the control group lost it (Watson et al., Journal of Bone and Mineral Research, 2018, DOI ↗ (external link)). Start with our beginner's resistance-training plan and read why strength training matters on a GLP-1. If you already have osteoporosis, build up under supervision rather than jumping straight to heavy loads.
Eating much less food makes it easy to fall short. The U.S. recommended daily allowance for calcium is 1,000 mg for most adults, rising to 1,200 mg for women over 50 and men over 70 (NIH Office of Dietary Supplements ↗ (external link)). Food sources such as dairy, fortified plant milks, canned fish with bones, and tofu set with calcium come first, with a supplement to fill the gap. Our supplements guide covers calcium and vitamin D. Whether you need extra vitamin D depends on your levels and sun exposure, so ask your clinician before taking high doses.
4. Aim for a steady pace
The real-world data link more weight loss to more bone loss. Extremely fast loss with very little food is hardest on both muscle and bone. If you are eating very little, raise it with your prescriber or a dietitian.
5. Get a bone density scan when it is warranted
The U.S. Preventive Services Task Force recommends DXA bone density screening for all women 65 and older and for younger postmenopausal women at higher risk (January 2025). For men, it found the evidence insufficient to recommend routine screening either way. If you are in a higher-risk group, ask whether a baseline scan before or early in treatment makes sense, with a repeat after a year or two of major weight loss. One distinction matters: the body-composition DXA many people get to track fat and muscle (see our DXA scan guide) reports whole-body bone, but osteoporosis is diagnosed from a dedicated hip-and-spine scan with a T-score. Ask for the right one. If you are tracking body composition anyway, our guide to reading your DXA results over time explains how to tell real change from noise.
6. Don't forget balance
Most fractures in older adults happen in falls. Strength and balance training reduce falls as well as protecting bone, and any dizziness from eating too little or dehydration is worth mentioning to your prescriber.
The bottom line
Large weight loss on any program costs a small amount of bone, mainly at the hip. The best evidence so far says GLP-1 medications do not raise fracture risk, but the long-term data are thin and semaglutide and tirzepatide have not been tested for bone as thoroughly as liraglutide. The trial with the clearest answer found that exercise combined with the medication kept bone density steady. Resistance and impact training, enough protein, calcium and vitamin D, and a well-timed bone scan if you are at higher risk are the ways to keep the weight loss and the skeleton.
This article is general education, not medical advice. If you have osteoporosis, a past fracture, or other bone risks, talk with your prescriber before changing your exercise, supplements, or treatment, and ask whether a bone density scan is right for you.Research findings above are attributed to PubMed-indexed articles with DOI links.
Should I get a bone density scan before or during GLP-1 treatment?
The U.S. Preventive Services Task Force recommends a DXA bone density scan for all women 65 and older and for younger postmenopausal women at higher risk; for men it found the evidence insufficient to recommend routine screening. If you are in a higher-risk group, ask your prescriber about a baseline scan and a repeat after a year or two of major weight loss. Make sure it is a hip-and-spine bone density scan, not only a body-composition DXA.
RCT in 160 obese older adults losing ~9% of body weight: total-hip BMD fell ~3% with aerobic exercise but only ~0.5-1% with resistance or combined training. Basis for resistance training as the key bone lever.
4Challenging
2Mixed findings
Related terms
CPAP — Continuous positive airway pressure: a bedside machine that blows gently pressurized air through a mask to hold the airway open during sleep, the standard first-line treatment for obstructive sleep apnea.
Related guides
Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching — For women, the biggest GLP-1 question is fertility. Tirzepatide can make the pill less reliable, weight loss can bring back ovulation you weren't expecting, and none of these drugs is safe in pregnancy, which is why "Ozempic babies" happen. This guide covers contraception and pregnancy planning, the PCOS trial evidence, protecting bone and muscle, the heart, and the menopause overlap.
CPAP as the weight comes off: managing sleep apnea on a GLP-1 — Tirzepatide (Zepbound) roughly halved sleep apnea severity in the SURMOUNT-OSA trials, and 42 to 50% of participants reached the trial's definition of resolution. That still left many with apnea, and the trials never tested stopping CPAP for good. This guide covers why you shouldn't retire your machine on your own, how pressure and mask fit change as weight comes off, when and how a repeat sleep test happens, and how an OSA diagnosis affects Zepbound coverage (as of September 2026).
How GLP-1 medications affect men vs. women: what the sex differences actually are — The same GLP-1 medication doesn't act quite the same in men and women. On average women lose more weight, report more side effects, and absorb more of the drug at the same body weight, differences driven partly by estrogen and testosterone. This guide covers what the research shows about sex differences in weight loss, tolerability, blood sugar and biology, and what it means for what you should expect.
Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching — For men, losing weight on a GLP-1 can raise testosterone that obesity was holding down, and unlike testosterone therapy it seems to leave fertility intact. This guide covers what the research shows so far on testosterone, sexual function and sperm, muscle and bone, heart health and sleep apnea, and why the routine checkup matters more on these medications.
Cortisol, stress, and weight on a GLP-1: what the connection really is — The "cortisol makes you fat" story is mostly overstated. Real cortisol excess, as in Cushing's syndrome, clearly drives central fat, but everyday stress does far less. On a GLP-1, cortisol matters more for muscle than for belly fat. This guide covers the evidence, how sleep affects cortisol, and why "cortisol-blocker" supplements don't hold up.